ZYMEWORKS INC. (ZYME) Current Ratio
- Current ratio · latest quarter: Value 6.32×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 6.32× | Current assets / current liabilities. $298.39M ÷ $47.24M ≈ 6.32× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 298.39M USD | Assets, Current |
| Current obligations | 47.24M USD | Liabilities, Current |
| Cash and equivalents | 179.41M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 5.93M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | |
| Payables | (m) | |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $298.39M | $47.24M | $179.41M | (m) | $5.93M | (m) | (m) | (m) | 6.32× |
| 2026-03-31 | $385.68M | $35.65M | $244.28M | (m) | $4.67M | (m) | (m) | (m) | 10.82× |
| 2025-12-31 | $248.77M | $42.32M | $41.16M | (m) | $4.64M | (m) | (m) | (m) | 5.88× |
| 2025-09-30 | $291.71M | $42.04M | $64.83M | (m) | $29.35M | (m) | (m) | (m) | 6.94× |
| 2025-06-30 | $296.13M | $38.50M | $98.25M | (m) | $2.63M | (m) | (m) | (m) | 7.69× |
| 2025-03-31 | $306.47M | $65.10M | $76.20M | (m) | $24.59M | (m) | (m) | (m) | 4.71× |
| 2024-12-31 | $300.45M | $88.29M | $66.10M | (m) | $55.81M | (m) | (m) | (m) | 3.40× |
| 2024-09-30 | $343.77M | $83.91M | $122.36M | (m) | $23.70M | (m) | (m) | (m) | 4.10× |
| 2024-06-30 | $383.50M | $54.71M | $70.96M | (m) | $32.08M | (m) | (m) | (m) | 7.01× |
| 2024-03-31 | $393.82M | $56.89M | $114.81M | (m) | $30.95M | (m) | (m) | (m) | 6.92× |
| 2023-12-31 | $412.93M | $55.76M | $157.56M | (m) | $19.48M | (m) | (m) | (m) | 7.41× |
| 2023-09-30 | $374.63M | $72.85M | $94.33M | (m) | $67.27M | (m) | (m) | (m) | 5.14× |
| 2023-06-30 | $420.34M | $93.55M | $142.10M | (m) | $48.82M | (m) | (m) | (m) | 4.49× |
| 2023-03-31 | $426.37M | $67.32M | $181.58M | (m) | $66.92M | (m) | (m) | (m) | 6.33× |
| 2022-12-31 | $544.71M | $95.63M | $400.91M | (m) | $33.40M | (m) | (m) | (m) | 5.70× |
| 2022-09-30 | $190.66M | $57.71M | $96.08M | (m) | $6.73M | (m) | (m) | (m) | 3.30× |
| 2021-12-31 | $288.22M | $71.85M | $201.87M | (m) | $15.61M | (m) | (m) | (m) | 4.01× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |